Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Has Consensus Price Target of $6.23

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have received a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $6.23.

Several equities research analysts have recently commented on IRWD shares. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Jefferies Financial Group raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Friday, September 25th. Finally, Weiss Ratings upgraded shares of Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership boosted its position in shares of Ironwood Pharmaceuticals by 724.5% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,397,242 shares of the biotechnology company’s stock valued at $11,924,000 after purchasing an additional 2,985,181 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Ironwood Pharmaceuticals by 529.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company’s stock valued at $7,307,000 after buying an additional 1,751,219 shares in the last quarter. Hillsdale Investment Management Inc. increased its position in Ironwood Pharmaceuticals by 6.9% during the 1st quarter. Hillsdale Investment Management Inc. now owns 1,236,628 shares of the biotechnology company’s stock valued at $4,341,000 after buying an additional 80,250 shares in the last quarter. Pacer Advisors Inc. bought a new position in Ironwood Pharmaceuticals during the 1st quarter valued at approximately $3,982,000. Finally, Ritholtz Wealth Management raised its stake in Ironwood Pharmaceuticals by 130.8% during the third quarter. Ritholtz Wealth Management now owns 831,091 shares of the biotechnology company’s stock valued at $3,299,000 after buying an additional 470,997 shares during the last quarter.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock opened at $4.68 on Friday. Ironwood Pharmaceuticals has a fifty-two week low of $2.31 and a fifty-two week high of $5.78. The firm has a market cap of $773.32 million, a P/E ratio of 5.20 and a beta of 0.25. The business’s 50 day moving average price is $3.92 and its 200-day moving average price is $3.96.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, November 5th. The biotechnology company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.04. The company had revenue of $133.04 million during the quarter, compared to the consensus estimate of $119.99 million. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. As a group, equities analysts predict that Ironwood Pharmaceuticals will post 1.10 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.